|
COMMERCE BUSINESS DAILY ISSUE OF JULY 30,1999 PSA#2399Centers for Disease Control and Prevention (CDC), Procurement & Grants
Office, SECTION III, 2920 Brandywine Road, Mailstop K-70, Atlanta, GA
30341-4146 Q -- PERFORM SUSCEPTIBILITY TESTING FOR ANTIMICROBIALS SOL 1999Q00249
DUE 081399 POC Susan Lyle, Purchasing Agent, (770) 488-2632 The
Centers for Disease Control and Prevention intends to procure the
services of a vendor to process blood culture bottles and agar slants
for bacteria, mycobacteria, and fungi, and to perform antimicrobial
susceptibility testing of isolated pathogens against antimicrobials
used in the United States and for the various antimicrobials used in
Malawi and Vietnam but not in the United States. The following testing
is required: (A) Analysis of bottles and slants: (1) 1,415 Myco
F/Lytic bottles are to be analyzed for bacteria, mycobacteria and
fungi; (2) 235 Myco-Chek bottles are to be worked-up for mycobacteria;
(3) 235 Middlebrook 7H11 agar slants to be processed for mycobacterial
growth; (4) 235 Inhibitory Mold Agar slats are to be processed for
fungi growth; (5) 235 Isolator chocolate agar slants are to be
processed for bacterial growth. (B) Frozen Isolates: (1) Identification
of 390 bacteria isolated from three culture systems; (2) Antimicrobial
susceptibility testing of these 390 bacterial isolates; (3)
Identification of 39 yeast isolates from three culture systems; (4)
antimicrobial susceptibility testing of 39 yeasts isolates; (5)
Identification of 160 mycobacterial isolates by gene probes,
biochemical tests and high performance liquid chromatography; (6)
antimicrobial susceptibility testing of 160 mycobacterial isolates; (7)
Restriction Fragment Length Polymorphism (RFLP) analysis of M.
tuberculosis isolates (approx 140 isolates); (8) Serotyping of 150
Salmonella isolates. In order to perform the required services, a
laboratory must be accredited by the College of American Pathologists,
and must be a large-volume diagnostic/research facility with reference
laboratory-level expertise in the isolation and identification of fungi
and mycobacteria. Personnel must have ten or more years experience
conducting comparative blood culture studies with documented
publications of these studies in the peer-reviewed medical literature.
In addition, the laboratory should have recent (over the past three
years) experience conducting bloodstream infection studies in
sub-Saharan Africa and Southeast Asia, and culturing blood from
patients in these regions for unexpected and emerging bacteria,
mycobacteria, and fungi. The laboratory must have approved Biosafety
level III containment facilities (detailed in "Biosafety in
Microbiology and Biomedical Laboratories" HHS Publication 93-8395) to
safely handle unknown, often dangerous, emerging pathogens responsible
for bloodstream infections. All interested parties are requested to
submit a written request to be provided an RFQ package. A sole source
procurement is anticipated. Requests must reflect the RFQ number,
reflected in Item 9 above. Submit requests to Sue Lyle at the above
address, Mailstop K70, or via e-mail at SIL2@cdc.gov, or by facsimile
at 770-488-2670 or 2671. A Request for Quotations will be issued on
approximately August 16, 1999. SIC 8071, 8069. Posted 07/28/99
(I-SN359940). (0209) Loren Data Corp. http://www.ld.com (SYN# 0077 19990730\Q-0005.SOL)
Q - Medical Services Index Page
|
|